ΤΣΑΤ
0.039
#5
bou bou Τρι. 9 Φεβ. 2021 15:30 4 views
μια ιστορια για πατεντες

Niels C. Pedersen, now professor emeritus at the UC Davis School of Veterinary Medicine, has been studying FIP since the 1960s. In 2018 and 2019, he tested a newly developed antiviral drug known as GS-441524 as a potential treatment. The Atlantic recently reported on Pedersen’s groundbreaking results: GS-441524 successfully cured naturally occurring FIP in 25 out of 31 cats in a field trial—“an unheard-of recovery rate.”


Developed by pharmaceutical company Gilead Sciences, GS-441524 defeats viruses by blocking their ability to replicate. By making a small change that improved the molecule’s ability to enter human cells, Gilead also created a second, nearly identical drug—remdesivir. 


While Gilead pursued remdesivir as a possible treatment for Ebola in humans, Pedersen tested the simpler drug, GS-441524, in cats. In collaboration with Gilead’s own researchers, he showed that GS-441524 cured FIP “safely and effectively.” 


But as the Atlantic article explains, this long-awaited victory over FIP quickly turned into a dead end. 


Gilead refused to license GS-441524 for use in animals. The company was working toward FDA approval of remdesivir for Ebola and feared that research on GS-441524 in cats might interfere with the approval of remdesivir for human use. 

...

Who can make Gilead's coronavirus drug, licence free